Welcome to our dedicated page for Pasithea Therapeutics SEC filings (Ticker: KTTAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pasithea Therapeutics Corp. filings document the formal reporting record for a clinical-stage biotechnology company with common stock and warrants registered on The Nasdaq Capital Market. The disclosures cover PAS-004-related corporate context, security classes, emerging growth company status, and material events reported on Form 8-K.
Recent regulatory filings include Nasdaq listing-compliance notices, executive officer appointments tied to clinical development leadership, and proxy materials for annual meeting matters. The proxy record addresses director elections, auditor ratification, equity compensation plan amendments, and capital-structure proposals, while 8-K filings report governance changes and other current events affecting the issuer and its listed securities.
Pasithea Therapeutics Corp. (KTTA) reports that Nasdaq has granted an additional 180-day period, until February 16, 2027, to regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing. The initial 180-day grace period had been set to expire on August 19, 2026. The company states it will continue monitoring its share price and may consider actions such as a reverse stock split to regain compliance. If compliance is not achieved within the extended period, Nasdaq may initiate delisting proceedings, which Pasithea would have the right to appeal.
Pasithea Therapeutics Corp. is a clinical-stage biotech developing treatments for RASopathies, MAPK pathway-driven tumors and CNS disorders, led by MEK inhibitor PAS-004, now in Phase 1 and Phase 1/1b trials for advanced tumors and NF1 plexiform neurofibromas. The company also has PAS-001 in discovery for schizophrenia.
For the quarter ended June 30, 2026, Pasithea reported a net loss of $5.3 million versus $3.7 million a year earlier, and a six‑month net loss of $8.1 million. Operating expenses rose as general and administrative spending reached $2.0 million and research and development climbed to $3.7 million for the quarter, reflecting expanded clinical, CMC and non‑clinical work on PAS‑004.
Cash and cash equivalents were $45.7 million at June 30, 2026, with total assets of $51.7 million and stockholders’ equity of $49.8 million. The company also has 54,828,835 paid but unexercised December 2025 pre‑funded warrants at a $0.001 exercise price. Management concluded there is no substantial doubt about the company’s ability to continue as a going concern for at least 12 months, but ongoing operations remain dependent on external financing.
Pasithea Therapeutics Corp. plans a virtual annual meeting on September 9, 2026 at 9:00 a.m. Eastern Time to vote on director elections, auditor ratification and a reverse stock split. Stockholders of record on July 24, 2026, when 33,414,448 shares of common stock were outstanding, may vote.
Stockholders will elect two Class III directors, Tiago Reis Marques and Lawrence Steinman, to terms ending in 2029, ratify CBIZ as independent auditor for 2026, and consider a Reverse Split Proposal. The board is classified, directors can be removed only for cause, and most directors are independent, with separate chair and CEO roles and active audit, compensation, and nominating committees.
In 2025, CEO Tiago Reis Marques received total compensation of $1,327,518, including salary and equity awards, and his 2026 base salary is $621,000 with a 55% bonus target. CFO Daniel Schneiderman received $895,187 in 2025, with a 2026 base salary of $456,000. New CMO Kartik Krishnan has a $500,000 base salary, 40% bonus target and options on 1,129,323 shares. Large holders each beneficially own up to 9.99%, while all directors and officers together own about 1.5% of shares. The 2024 audit report included an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.
Opaleye Management Inc., Opaleye, L.P., and James Silverman report beneficial ownership of Pasithea Therapeutics Corp. common stock. Through Opaleye, L.P., they collectively report holding 2,050,000 shares of common stock, representing 6.14% of the outstanding class.
The stake is calculated based on 33,414,448 shares outstanding as of May 13, 2026, as reported by Pasithea Therapeutics. The Reporting Persons have shared voting and dispositive power over all 2,050,000 shares and no sole voting or dispositive power. The filing clarifies that this does not constitute an admission of beneficial ownership for any legal purpose.
Pasithea Therapeutics Corp. ownership disclosure: Coastlands entities and Matthew D. Perry report beneficial ownership of 3,835,035 shares of Common Stock, representing 11.48% of the class. The calculation is based on 33,414,448 shares outstanding as of May 13, 2026 per the registrant's Form 10-Q. The filing excludes pre-funded warrants held in excess of a 9.99% beneficial ownership limitation.
Pasithea Therapeutics Corp. ownership disclosure: Stonepine entities and Jon M. Plexico report shared beneficial ownership of 1,952,550 shares of Common Stock, representing 5.8% of the class as calculated on 33,414,448 shares outstanding as of May 13, 2026. The holdings are reported as shared voting and dispositive power; each reporting person disclaims group membership and sole beneficial ownership beyond their pecuniary interest.
Pasithea Therapeutics Corp. insider Coastlands Capital LP reported an open-market purchase of 100,000 shares of common stock at $0.53 per share. After this transaction, Coastlands Capital LP is shown as indirectly owning 3,835,035 common shares through its investment partnership structure.
The filing notes that Coastlands Capital LP, its related general partners and control person Matthew Perry are reporting jointly and each disclaims beneficial ownership of the common stock beyond any pecuniary interest. Coastlands Capital LP is identified as a more than ten percent owner of Pasithea Therapeutics.
Pasithea Therapeutics Corp. reported a net loss of $2.9 million for the quarter ended March 31, 2026, narrower than the prior-year loss. The company is ramping investment in its PAS-004 clinical programs while benefiting from higher interest income and warrant valuation gains.
Research and development spending rose to $2.9 million as Phase 1 trials in advanced tumors and NF1-related plexiform neurofibromas progressed. Pasithea ended the quarter with $50.4 million in cash and equivalents and working capital of about $51.2 million, and management believes this is sufficient for at least 12 months.
Pasithea Therapeutics Corp Schedule 13G/A discloses ownership by Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC. The filing reports 1,350,896 shares held with 5.4% of the class (CUSIP 70261F202). Ameriprise states CMIA’s holdings are included in AFI’s total and both entities disclaim beneficial ownership. The filing is signed by Michael G. Clarke and attaches exhibits identifying the acquiring subsidiary and a joint filing agreement.
Pasithea Therapeutics Corp. reported that Chief Executive Officer Tiago Marques received a stock option grant covering 1,756,069 shares of common stock. The option has an exercise price of $0.841 per share and expires on April 30, 2036.
According to the grant terms, 33% of the underlying shares vest on the one-year anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the following two years, as long as he remains in continuous service. All unvested shares fully vest upon a Change in Control under the company’s 2023 Stock Incentive Plan. Vested options may generally be exercised for up to three years after termination of continuous service, other than for cause.